Markets:

Overview

News

Currencies

International

Treasuries

Seagen Inc. - Common Stock (NQ:SGEN)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc. - Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2021 ↗

November 09, 2021

Upgrades JP Morgan upgraded the previous rating for New Relic Inc (NYSE:

Via Benzinga

Seagen to Highlight Two Novel Antibody-Drug Conjugates (ADCs) at the SITC 36th Annual Meeting

November 09, 2021

From Seagen Inc.

Via Business Wire

Expert Ratings For Seagen ↗

October 29, 2021

Seagen (NASDAQ:SGEN) has observed the following analyst ratings within the...

Via Benzinga

Earnings Scheduled For October 28, 2021 ↗

October 28, 2021

Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million. •...

Via Benzinga

Notable Seagen Insider Trades $7.4M In Company Stock ↗

November 04, 2021

Jean I Liu, Gc/EVP And Leg Afairs at Seagen (NASDAQ:SGEN), made a large buy and sell of company shares on November 1, according to a new SEC filing. What Happened: A Form 4 filing...

Via Benzinga

Topics Regulatory Compliance

Seagen to Highlight Multiple ADCETRIS® (brentuximab vedotin) Data Presentations at the Upcoming 2021 American Society of Hematology (ASH) Annual Meeting

November 04, 2021

From Seagen Inc.

Via Business Wire

CNBC's Final Trades: Seagen, Dollar Tree And This Pharma Major ↗

November 04, 2021

On CNBC’s “Halftime Report Final Trades,&rd...

Via Benzinga

Notable Seagen Insider Trades $7.4M In Company Stock ↗

November 03, 2021

Todd E Simpson, Chief Financial Officer at Seagen (NASDAQ:SGEN), made a large buy and sell of company shares on October 29, according to a new SEC filing. What Happened: A Form 4...

Via Benzinga

Topics Regulatory Compliance

The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs ↗

October 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc...

Via Benzinga

Seattle Genetics (SGEN) Q3 2021 Earnings Call Transcript ↗

October 29, 2021

SGEN earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Seagen Reports Third Quarter 2021 Financial Results

October 28, 2021

From Seagen Inc.

Via Business Wire

Seattle Genetics's Earnings Outlook ↗

October 27, 2021

Seattle Genetics (NASDAQ:SGEN) is set to give its latest quarterly earnings report on Thursday, 2021-10-28. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

10 Biggest Price Target Changes For Wednesday ↗

October 27, 2021

Raymond James raised Alphabet Inc. (NASDAQ:GOOGL

Via Benzinga

2 Stocks That Have Doubled the S&P 500's Returns Over the Past 5 Years and Could Still Go Higher ↗

October 22, 2021

These companies just keep on growing.

Via The Motley Fool

Topics Stocks

Health Care Sector Appears to Be a Drag on Positive UnitedHealth Earnings ↗

October 15, 2021

Stock futures were pointing to a higher open even before Goldman Sachs (NYSE: GS) reported better than expected earnings. Goldman rose 2.25% before the open helping to...

Via Benzinga

Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) With Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer

October 12, 2021

From Seagen Inc.

Via Business Wire

Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2021 Financial Results on October 28, 2021

October 07, 2021

From Seagen Inc.

Via Business Wire

Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates ↗

October 01, 2021

Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new...

Via Benzinga

A Bullish Sign Appears On Seagen's Chart ↗

September 30, 2021

If history is any guide, there may be good fortune ahead for shares of Seagen(NASDAQ:SGEN). A so-called "golden cross" has formed on its chart and, not surprisingly,...

Via Benzinga

Seagen Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA® (Tucatinib) Regimen in HER2-Positive Metastatic Colorectal Cancer

September 28, 2021

From Seagen Inc.

Via Business Wire

Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer

September 27, 2021

From Seagen Inc.

Via Business Wire

Why Genmab's Stock Is Trading Higher Today ↗

September 21, 2021

Genmab A/S (NASDAQ:GMAB) shares are trading higher after the company, along with Seagen Inc. (NASDAQ: SGEN), announced the FDA has granted accelerated approval to...

Via Benzinga

Why Seagen's Stock Is Trading Higher Today ↗

September 21, 2021

Seagen (NASDAQ:SGEN) shares are trading higher after the company, along with Genmab A/S (NASDAQ: GMAB), announced the FDA has granted accelerated approval to TIVDAKTM...

Via Benzinga

FDA Gives Accelerated Approval to Seagen - Genmab's ADC In Cervical Cancer ↗

September 21, 2021

The FDA handed an accelerated approval to Seagen Inc (NASDAQ: SGEN) and Genmab A/S’ (NASDAQ: GMAB) Tivdak (tisotumab vedotin-tftv, or TV). The...

Via Benzinga

Seagen to Host Conference Call and Webcast Discussion on September 21, 2021 to Discuss TIVDAK™ (tisotumab vedotin-tftv) Approval

September 20, 2021

From Seagen Inc.

Via Business Wire

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data ↗

September 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics...

Via Benzinga

Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer

September 20, 2021

From Genmab A/S

Via Business Wire

Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer

September 20, 2021

From Seagen Inc.

Via Business Wire

Seagen, Genmab Present Tisotumab Vedotin Combo Data In Cervical Cancer ↗

September 20, 2021

Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) have interim data from two Phase 1b/2 innovaTV 205 trial cohorts. The trial is evaluating its...

Via Benzinga

Seagen and Genmab Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021

September 19, 2021

From Seagen Inc.

Via Business Wire

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Seagen Inc. - Common Stock (NQ:SGEN)

All News about Seagen Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today